Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.
Zacks
More News
Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure
COO's MyDay, MiSight and fertility strengths support the long-term case, but Asia-Pacific softness, recall costs and leverage keep the stock in wait-and-see mode.
Zacks
How COO Is Balancing Premium Lens Growth Against Asia-Pacific Risks?
COO's premium lens, myopia control and fertility momentum support growth, but Asia-Pacific weakness and margin pressure keep the outlook measured.
Zacks
How COO Is Riding Myopia and Fertility Trends Amid Execution Risks
COO's premium lenses, MiSight and fertility trends support growth, but Asia-Pacific softness, portfolio shifts and cost pressure keep execution in focus.
Zacks
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Zacks
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Zacks
Reasons to Retain STE Stock in Your Portfolio for Now
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.